MLEC (malectin) is a carbohydrate-binding protein localized to the endoplasmic reticulum and plasma membrane with specificity for Glc2-N-glycans, suggesting a role in early protein N-glycosylation. The protein functions as a regulator of macrophage polarization; in vitro studies demonstrate that MLEC promotes M1 to M2 macrophage differentiation 1. Disease relevance emerged from genetic association studies identifying MLEC polymorphisms (rs10431386 and rs7964786) significantly associated with cerebral palsy risk in a Chinese Han population (OR=1.587-1.956). Mechanistically, risk alleles reduce MLEC expression in patient blood and macrophage cell lines, and this decreased expression impairs M1 to M2 macrophage polarization, suggesting that altered MLEC-mediated immune regulation contributes to cerebral palsy pathogenesis 1. The clinical significance lies in identifying MLEC as a potential genetic biomarker for cerebral palsy susceptibility and as a therapeutic target through immune modulation. Additional cellular studies indicate MLEC participates in protein-folding chaperone interactions, supporting its role in endoplasmic reticulum protein quality control during glycoprotein synthesis. Further investigation is needed to clarify MLEC's broader roles beyond macrophage biology and to determine whether MLEC-targeted therapeutics could prevent or modify cerebral palsy progression.